NOD2 and TLR2 recognize components of bacterial cell wall peptidoglycan and direct defense against enteric pathogens. CD8 + T cells are important for immunity to such pathogens but how NOD2 and TLR2 induce antigen specific CD8 + T cell responses is unknown. Here, we define how these pattern recognition receptors (PRRs) signal in primary dendritic cells (DCs) to influence MHC class I antigen presentation. We show NOD2 and TLR2 phosphorylate PI31 via TBK1 following activation in DCs. PI31 interacts with TBK1 and Sec16A at endoplasmic reticulum exit sites (ERES), which positively regulates MHC class I peptide loading and immunoproteasome stability. Following NOD2 and TLR2 stimulation, depletion of PI31 or inhibition of TBK1 activity in vivo impairs DC cross-presentation and CD8 + T cell activation.
Introduction
NOD2 and TLR2 are pattern recognition receptors (PRRs) that recognize conserved components of peptidoglycan (PGN) found in bacterial cell walls (1, 2) . Both PRRs activate intracellular signaling pathways in antigen presenting cells (APCs) that drive pro-inflammatory and antimicrobial adaptive responses. Both receptors are important for clearance of bacterial pathogens such as Salmonella typhimurium, Shigella flexneri and Mycobacterium tuberculosis (3) (4) (5) . Both NOD2 and TLR2 employ distinct signaling cascades to drive pro-inflammatory cytokine responses, however, the mechanism by which they connect to MHC class I antigen presentation machinery is unclear.
NOD2 cross-talks with TLR2 in myeloid cells. This manifests as amplification in signaling culminating in greatly heightened pro-inflammatory cytokine responses (6,7). Furthermore, gene expression studies have revealed dual activation of both receptors leads to a transcriptional programme that not only amplifies the differential expression common to both receptors, but leads to induction of a specific NOD2/TLR2 gene panel highlighting a physiological role for this cross-talk in differentiating pathogenic versus commensal invasion of APCs (8, 7, 9) . NOD2 is the strongest associated Crohn's susceptibility gene and Crohn's disease patients who express NOD2 polymorphisms display loss of function for induction of NOD2 effector genes and NOD2/TLR2 specific genes (10, 7, 11) .
NOD2 and TLR2 activate autophagy in myeloid cells to degrade invading bacteria and facilitate MHC class II antigen presentation (12) (13) (14) . Stimulation of either receptor regulates Th1, Th2 and Th17 immune responses (15) (16) (17) (18) . DCs that have engulfed bacteria also present exogenous antigens on MHC I via cross-presentation, which is critical for CD8 + T cell responses against microbial pathogens (19) . Proposed pathways and mechanisms underlying cross-presentation include the phagocytic pathway, which exports antigens from the phagosome to the cytosol, degradation by the immunoproteasome and peptide loading in the endoplasmic reticulum (ER) or in phagosomes (20) . Alternatively, in cross-presentation through the vacuolar pathway, endosomal or phagosomal proteases degrade internalised antigens independent of immunoproteasomal degradation and loading MHC class I molecules occur in endocytic compartments (21) .
Dendritic cells were left unstimulated or stimulated with 10 µg/ml MDP or 1 µg/ml PAM 3 CSK 4 or both at the indicated time points. In some experiments, other PRR ligands were used including LPS 100 ng/ml, and R848 1 µg/ml (Invivogen) or cells were treated with the small molecule inhibitors Ponatinib (50nM) or BX795 (1mM) for 1 hr. Following stimulation, cells were harvested on ice and washed once with cold Hanks Buffered Saline (HBS). Phosphoenrichment was then performed using a cellular phosphoenrichment kit (Qiagen). Briefly, cells were lysed in phosphoprotein lysis buffer containing 0.25% CHAPS with phosphatase inhibitor cocktail 3 (Sigma), protease inhibitor tablet (Qiagen) and the nuclease 0.0002% Benzonase (Qiagen) at 4°C for 40 min. Samples were centrifuged and the supernatants harvested for protein quantification by BCA. Aliquots of whole cell lysate (WCL) were kept for subsequent immunoblots. Samples were then loaded onto the phosphoenrichment columns, before eluting the phosphoenriched fraction using an elution buffer containing 0.25% CHAPS (Qiagen). Following concentration of the eluted fraction using 9k molecular weight cut-off concentrator columns (Thermo Scientific), protein concentration was measured by BCA. LDS sample buffer (Life Technologies) and dithiothreitol (Sigma) was added, before heating to 70°C for 5 min. Protein samples were separated by SDS-PAGE and transferred onto PVDF or nitrocellulose membranes using iBlot2 dry blotting system (Invitrogen). Membranes were blocked in 5% (w/v) BSA or non-fat dry milk diluted in TBST for 1 hour at room temperature (RT). Primary antibodies were then added and incubated at manufacturers recommended dilution, temperature and time. Membranes were washed in TBST three times for 5-10 min. Species-specific HRP-conjugated secondary antibody was added to TBST with 5% (w/v) non-fat dry milk at the manufacturers recommended dilution.
Membranes incubated in this solution for 1 hour at RT with gentle mixing. Membranes were washed 4 times for 5-10 min in TBST and developed by enhanced chemiluminescence (ECL) solution (Amersham). Densitometric analysis of Western blots was performed using ImageJ software.
ShRNA lentiviral transduction and siRNA transfection
Short hairpin RNA lentiviral particles were produced and transduced following the RNAi Consortium (TRC) protocols. ShRNA containing pLKO.1 vectors targeting NOD2 (SHCLND-NM_022162), PI31 (SHCLND-NM_006814), TBK1 (SHCLND-NM_013254) or non-Target shRNA Control Plasmid DNA were all obtained from Sigma (MISSION shRNA Plasmid DNA).
Briefly, HEK293T packaging cells growing in 6 cm well plate were transfected with a mix of 1 µg packaging vector (psPAX2), 0.4 µg envelope vector (pMD2.G) and 1.6 µg hairpin-pLKO.1 vector (SHC016 control or gene specific shRNA. Fugene-6 (Promega) was used as transfection reagent. Cell culture medium containing lentiviral particles (LVP) was collected 48 h later and passed through a 0.45 µm filter (Sartorius). Virus preparations were then concentrated by centrifugation at 30,000 rpm for 90 min. Viral particles were added to cultured THP-1 cells in R10 together with 8 µg/ml Polybrene (Sigma) to improve transfection efficiency. Following incubation for 3 hrs at 37°C, the cells were harvested, washed, and resuspended at 1x10 6 cells/ml in R10 media with antibiotics including puromycin (as selective antibiotic). After 10 days of continuous selection with puromycin, knockdown efficiency was assessed by immunoblot.
Transfection of human dendritic cells was performed by electroporation of SMARTpool ON-
TARGETplus human Psmf1 (PI31) or non-targeting siRNAs (Dharmacon). Cells were resuspended in the solution provided with the kit (Invitrogen) followed by electroporation with Neon System kit (Invitrogen) using the following parameters: 1475 V, 20 ms, 2 pulses. BMDCs transfection was performed by electroporation of SMARTpool ON-TARGETplus mouse Psmf1, SEC16A or non-targeting siRNAs (Dharmacon) following the manufacturer's instructions (Amaxa). Briefly, BMDCs were harvested at day 7 and resuspended in the electroporation solution provided with the kit. Cells were distributed per cuvette and electroporated. After 48 hrs, cells were harvested and knockdown analyzed by Western Blot.
Immunoprecipitation, in-gel and in-solution digestions
Cells were lysed in IP lysis buffer (50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 5 mM EDTA, 1% TritonX-100) containing protease and phosphatase inhibitor cocktail (Sigma). The lysate was centrifuged for 20 min at 4°C. The supernatant were collected and incubated with indicated antibodies or control isotype IgG for 4 hrs at 4°C. Protein G coupled magnetic beads (Invitrogen) were added and incubated for 1 hour at 4°C. The beads were washed with lysis buffer four times and protein samples eluted by incubation in LDS sample buffer with 50 mM DTT for 10 min at 70°C and analysed by SDS-PAGE and Western blotting using indicated antibodies.
Alternatively, Pierce IgG elution buffer (Pierce; 210044) was added to beads for 30 min at 4°C with gentle agitation. For in-gel digestion, gel bands were cut into 1-2 mm 3 cubes and were destained overnight with 50% methanol and 5% acetic acid in water. The samples were dried with acetonitrile and successively reduced with 10 mM DTT and alkylated with 50 mM iodoacetamide for 30 min at room temperature. The cubes were washed with 100 mM ammonium bicarbonate, dried with acetonitrile and digested with 400 ng elastase in 25 mM ammonium bicarbonate overnight at 37°C. Peptides were then extracted using three consecutive incubations of 10 min with a 25 mM ammonium bicarbonate followed by 50% acetonitrile and 5% formic acid in water and then 85 % acetonitrile and 5% formic acid in water. The samples were dried and resuspended in 1% acetonitrile and 0.1% TFA in water for LC-MS/MS analysis.
For in-solution digestion, 35 µl of each IP eluate were suspended in 175 µl of water, reduced with 5 mM dithiothreitol followed by alkylation with 20 mM iodoacetamide for 1 hour at room temperature. Protein was precipitated using chloroform-methanol and re-suspended in 6 M urea in 0.1 M Tris pH 7.8. Protein material was digested with 600 ng Trypsin (Promega) overnight at 37°C at 300 rpm. The samples were desalted using C18 cartridge (Waters). Briefly, samples were conditioned with buffer A (1% acetonitrile, 0.1% TFA in water) prior equilibration with buffer B (65% acetonitrile, 0.1% TFA in water). Acidified peptides were loaded onto the column, washed with buffer A and eluted with buffer B. The solution containing the peptides was dried and resuspended in 1% acetonitrile, 0.1% TFA in water for LC-MS/MS analysis.
qRT-PCR
Total RNA was purified using the RNeasy Mini Kit (Qiagen). cDNA was synthesised using a High Capacity RNA-to-cDNA kit (Applied Biosystems). Both procedures were performed according to the manufacturers' protocols. qRT-PCR was performed using Taqman chemistry (Applied Biosystems).
Taqman probes for NOD2 (Hs01550753_m1) and RPLP0 (Hs99999902_m1) and TaqMan Gene Expression Master mix were used. Real-time PCR was performed using a Bio-Rad C1000 Thermal cycler CFX Realtime system (Bio-Rad). Relative NOD2 gene expression was calculated in comparison to the RPLP0 control.
Kinase assay
The TBK1 kinase assay was performed using the TBK1 Kinase Enzyme System (Promega) and ADP-Glo Kinase Assay kit (Promega) using the following peptides as substrate:
IHEQWEKANVSSPHREFPPA (wild type PI31), IHEQWEKANVASPHREFPPA (mutated in Alanin 152), IHEQWEKANVSAPHREFPPA (mutated in Alanin 153) and
IHEQWEKANVAAPHREFPPA (mutated in Alanins 152 and 153). Kinase Detection reagent was added to convert ADP to ATP, and the newly synthesized ATP was converted to light using the luciferase/luciferin reaction.
HLA-I-associated peptide purification. All steps were carried out below 4°C. Briefly, cell pellets were lysed using 10 ml lysis buffer (1% Igepal 630, 300 mM NaCl, 100 mM Tris pH 8.0) per 10 9 cells and homogenized by mild sonication. Lysates were cleared in two subsequent centrifugation steps, one at 300 g for 10 min to remove nuclei and the other at 15,000 g for 30 min to pellet other insoluble material. HLA complexes were captured using 1 ml W6/32conjugated immunoresin (1 mg/ml) prepared in a column format at a flow rate of 1.5 ml/min and washed using subsequent runs of 50 mM Tris buffer, pH 8.0 containing first 150 mM NaCl, then 400 mM NaCl and no salt. HLA-peptide complexes were eluted using 5 ml 10% acetic acid and dried. Samples were loaded onto on a 4.6 x 50 mm ProSwiftTM RP-1S column (ThermoFisher) in 120 µl buffer A (0.1% formic acid in water) and eluted using a 500 µl/min flow rate over 10 min from 2 % buffer A to 35 % buffer B (0.1% formic acid in acetonitrile) with an Ultimate 3000 HPLC system (Thermo Scientific). One ml fractions were collected from 2 to 15 min.
Protein detection was performed at 280 nm absorbance. Fractions up to 12 min that did not contain ß 2 -microglobulin were combined, dried and resuspended in 1% acetonitril, 1% formic acid in water for LC-MS/MS analysis. MS data analysis. MS data was analysed using Mascot 2.5 and Peaks 7.5. Search parameters were set as follows: in-solution IP samples -enzyme specificity: trypsin, fixed modificationcarbamidomethylation, precursor mass tolerance -5 ppm, fragment mass tolerance -0.3 Da. Data acquired from elastase digested material was searched with identical parameters using no enzyme specificity. A final FDR cut-off of 1% was applied to both datasets. Data generated from HLA-I-associated peptide preparations was searched using no enzyme specificity, no modifications and precursor mass tolerance of 5 ppm and fragment mass tolerance of 0.03 Da.
Liquid chromatography tandem mass spectrometry (LC-MS-MS
All data was searched against all human protein sequences in the Uniprot database. FDR was <5% at a score cut-off of 15 for all samples. Quantitative analysis of the IP datasets was performed with Progenesis QI 3.0 (Nonlinear Dynamics). Protein quantitation was performed with non-conflicting peptides only.
Purification of proteasomal proteins
Cells were lysed in proteasome lysis buffer (50 mM Tris-HCl (pH 8.0), 1 mM DTT, 5 mM EDTA, 5 mM MgCl 2 , 10% glycerol, 2 mM ATP) containing a protease and phosphatase inhibitor cocktail by five freeze and thaw cycles. Lysates were sonicated and centrifuged for 20 min at 4ºC. The supernatants were collected and pre-cleared by agarose beads for 1 hr at 4 ºC. 
Confocal Microscopy
Following electroporation of pcDNA5 GFP-PI31 (Amaxa), cells were placed on poly-L-lysinecoated glass coverslips and incubated at 37°C in an atmosphere of 5% CO2. Cells were left unstimulated or stimulated with 10 µg/ml MDP and 1 µg/ml Pam 3 CSK 4 for 30 min. After extensive washing with cold PBS, cells were fixed with 2% (vol/vol) paraformaldehyde during 10 min at 4°C and quenched by adding 0.1 M glycine. Cells were permeabilized in PBS containing 0.05% (vol/vol) saponin and 0.2% (vol/vol) BSA for 20 min at room temperature, washed, and incubated first with primary antibodies for 1 hr and then with secondary antibodies for 45 min at RT. After washing, the coverslips were mounted with Vectashield (Vector Laboratories). Image acquisition was performed on a Zeiss inverted confocal LSM 880 microscope. Analysis was performed using Fiji software.
Phagosome isolation and analysis
BMDC were pulsed with equal numbers of unconjugated 3 um magnetic streptavidin microspheres or magnetic streptavidin microspheres (Bangs Laboratories) conjugated with biotinylated MDP (10 ug/ml) and PAM 3 CSK 4 (1 ug/ml) or biotinylated LPS (100 ng/ml) in a 1:2 ratio of BMDC: beads for 3 hrs. Cells were suspended in homogenization buffer (HB) (250 mM sucrose, 0.5 mM EGTA, and 20 mM HEPES/KOH) containing protease and phosphatase inhibitor cocktail and disrupted by sonication. Phagosomes containing the magnetic beads were isolated from homogenate using a magnet (Invitrogen). For western blot analysis, the magnetic beads were lysed in elution buffer (50 mM Tris, pH 7.9, 300 mM NaCl, 1% Triton) along with protease and phosphatase inhibitor cocktail for 30 min at 4ºC with gentle agitation. Protein concentrations were measured by Bradford assay. Isolated phagosome proteins (2 ug) and whole cell lysate (15 ug) were analysed by western blot.
In Vitro Cross-Presentation Assays
BMDCs were left unstimulated or stimulated with 10 µg/ml MDP and 1 µg/ml PAM 3 CSK 4 and incubated with sOVA or SIINFEKL peptide for 3 hrs. After extensive washing, BMDCs were incubated with CD8 + lymphocytes (72 hrs) isolated from C57BL/6 OT-1 transgenic mice and purified by negative immunomagnetic bead selection (Miltenyi-Biotec). Cross-presentation was evaluated by detecting expression of CD69 + on CD8 + lymphocytes by FACS.
In Vivo inhibition of TBK1 activity and cross-presentation assay
Mice were injected intraperitoneally with Amlexanox (10mg/Kg, Invivogen). After 24 hrs, the same amount of Amlexanox was injected again intraperitoneally with 100 µg MDP (Invivogen) and 10ug of PAM 3 CSK 4 . DMSO diluted in endotoxin-free PBS was injected as a control. After 12 hrs, sOVA was injected intravenously (250 ug), and spleens were harvested after 3 hrs. DCs were purified by CD11c negative selection (Miltenyi). DC activation was determined by upregulation of the co-stimulatory molecules MHC-II, CD86 and CD40. DCs were co-cultured with purified CFSE-OT-I CD8 + T cells for 3 days. T cell proliferation was measured by CSFE staining by FACS.
Generation of HLA-A2 NY-ESO-1 157-165 T cell clones
NY-ESO-1 specific CD8 + CTL clone was sorted directly using HLA-A2 NY-ESO-1 157-165 tetramers from a melanoma patient, as previoulsy described (28). After expansion, CTLs were stimulated with a mixture of allogeneic irradiated PBMCs and LG2 cells in the presence of 5 µg/ml phytohaemagglutinin and cultured over 16 days at 37 o C, 5% CO2 in RPMI-1640
(Invitrogen) supplemented with 10% (v/v) human serum, 2 mM Glutamax, 50-100 U/ml penicillin and 100 µg/ml streptomycin, 10 mM HEPES, 50 µΜ 2-mercaptoethanol, 1 mM sodium pyruvate, non-essential amino acids and 400 U/ml recombinant human IL-2 (Novartis).
Statistical and data analysis. Data were analyzed with Graph Pad Prism, and the Student's t test or one-way ANOVA for multiple comparisons was used to compare data sets throughout this study. P < 0.05 was considered significant.
Results

NOD2 and TLR2 stimulation induce PI31 phosphorylation
We first delineated NOD2 and TLR2 signaling in primary human DCs using quantitative phospho-proteomic analysis. We compared NOD2 S1 ). PI31 was highly abundant among the proteins differentially regulated in response to MDP (Table 1, fig.1C ).
PI31 has been linked to proteasome function (29,30) but no previous studies have reported its phosphorylation and association with innate immune pathways. Therefore, we speculated that PI31, given its link to proteasome, might be a suitable candidate to trigger MHC class I antigen presentation on NOD2 and TLR2 sensing. First, we confirmed that NOD2 activation by MDP, TLR2 activation by PAM 3 CSK 4 or their combination, induced PI31 phosphorylation ( fig. 1 D, E). We used phosphorylated MAPK (p38) in PE lysates as a positive marker of MAPK activation. We then determined whether NOD2 was required for PI31 phosphorylation. Using short hairpin RNAs (shRNA) targeting NOD2, we downregulated NOD2 expression in THP-1 cells ( fig. 1F ). We assayed protein levels of phosphorylated PI31 following stimulation with MDP, PAM 3 CSK 4 or a combination of both ligands. We found reduced PI31 phosphorylation after MDP exposure in NOD2 knockdown cells ( fig. 1G ). Reduced levels of PI31 phosphorylation were also observed following stimulation with PAM 3 CSK 4 or a combination of both MDP and PAM 3 CSK 4 suggesting that NOD2 may also amplify TLR2-dependent phosphorylation of PI31 ( fig.1G ). S2A , B). We also examined whether PI31 modulates NOD2/TLR2-induced secretion of proinflammatory cytokines. PI31 expression was downregulated in primary DCs using siRNA prior to stimulation with MDP and PAM 3 CSK 4 or LPS. PI31 knockdown did not modulate cytokine secretion as detected by levels of TNF and IL-6 ( Fig. S2C, D) . These data demonstrate that stimulation of DCs with NOD2 and TLR2 ligands induces phosphorylation of PI31, a protein that alters the function of the proteasome. PI31 activation by NOD2/TLR2 signaling did not affect NF-κB and MAPK activation or cytokine production in DCs.
TBK1 mediates NOD2 and TLR2 mediated PI31 phosphorylation
NOD2 stimulation triggers the formation of a protein complex containing RIPK2 and TRAF3
(tumour-necrosis-factor-receptor-associated factor 3), an E3 ligase that mediates Lys63-linked ubiquitination, through a serine/threonine-protein kinase TBK1 dependent mechanism (35,36).
To determine whether TBK1 forms a protein complex with PI31, we co-expressed HA-tagged PI31 and FLAG-tagged TBK1 in HEK293 cells expressing human NOD2 (hNOD2) and stimulated the cells with MDP. We immunoprecipitated HA-PI31 from cellular extracts and detected the presence of FLAG-TBK1 by immunoblot of the immunoprecipitated material. This result suggests that PI31 and TBK1 are in the same complex ( fig. 1A ) with increased detection of TBK1 co-immunoprecipitating with PI31 following MDP treatment. We then expressed FLAG-TBK1 and GFP-PI31 in hNOD2 HEK293 cells and stimulated them with MDP. Coimmunoprecipitation of FLAG-TBK1 and GFP-PI31 confirmed the presence of TBK1 and PI31
in the same complex. We found increased levels of GFP-PI31 following MDP stimulation,
suggesting an increased recruitment of PI31 co-immunoprecipitating with TBK1 following NOD2 activation ( fig. 2B ).
We next examined whether PI31 phosphorylation following NOD2 and TLR2 activation requires TBK1 kinase activity. We pre-treated primary human DCs with a TBK1 inhibitor, BX795, which specifically inhibits the catalytic activity of TBK1 (37), followed by DC stimulation with MDP, PAM 3 CSK 4 or a combination of both ligands. Pharmacologic inhibition of TBK1 significantly reduced PI31 phosphorylation after NOD2 and TLR2 stimulation. (fig. 2C ).
Next, we sought to identify the residue on which PI31 is phosphorylated following NOD2 and TLR2 activation. We immunoprecipitated endogenous PI31 from cellular extracts of THP1 cells 2D ). We next validated the mass spectrometry data by using a luminescent in vitro kinase assay that measures the amount of ADP formed from the TBK1 kinase reaction. First, we titrated the TBK1 enzyme in the presence of a PI31 sequence peptide containing both serines 153 and 152 ( fig 2E) . We examined mutated peptides for serine 152 (alanine 152), serine 153 (alanine 153) or both with the in vitro kinase assay, which confirmed PI31 was directly phosphorylated at serine 153 and, to a lesser extent, at serine 152 ( fig 2F) .
These results demonstrate that TBK1 forms a complex with PI31 and may be required for its phosphorylation on serine 153 on NOD2 and TLR2 sensing.
PI31 modulates the quantity of MHC class I loaded peptides in DCs
Proteasomes remove abnormal proteins from the cytosol and contribute to proteolysis required for MHC-class I antigen-processing (38) (39) (40) . Most proteasomal degradation depends on recognition of poly-ubiquitinated proteins (41). As PI31 interacts with and inhibits proteasomes (30), we wanted to determine whether its phosphorylation via NOD2/TLR2 leads to its polyubiquitination and degradation by the proteasome. We stimulated DCs with MDP and PAM 3 CSK 4 for 45 or 180 min and then collected the lysates for PI31 immunoprecipitation.
Precipitates were immunoblotted using anti-ubiquitin (FK2) antibody. We did not detect poly- Using reverse-phase HPLC, we separated eluted peptides from the α-chain and β 2 -microglobulin of the HLA complexes and analysed eluted peptide fractions by LC-MS/MS. Mass spectrometry analysis showed that PI31 knockdown reduced the total number of peptides eluted compared to cells expressing PI31 ( fig. 3C, D) . The peptide motifs were not significantly modulated by PI31
suggesting that its effect is unlikely restricted to generating specific type HLA class I associated peptides ( fig. 3E ). We next tested whether PI31 modulates the number of assembled β 2microglobulin MHC-I complexes competent for surface antigen presentation. We used siRNAs to knockdown PI31 in primary DCs ( fig. 3F ), followed by measurement of β 2 -microglobulin before (lysate) and after (supernatants) capturing HLA class I complexes. The abundance of β 2microglobulin peptides detected by LC-MS/MS was not significantly modified by PI31 before or after capturing HLA-class I complexes ( fig. 3G, H) . This confirmed PI31 affects generation of different HLA class I associated peptides rather than quantity of surface MHC I.
Next, we investigated the mechanism through which PI31 modifies the number of HLA class I associated peptides by regulating constitutive and immunoproteasome subunit composition.
Using THP-1 cells with knocked down PI31 by shRNA, we immunoprecipitated PSMA2 (MCP21), a 20S core alpha subunit, and examined the levels of constitutive or immunoproteasome subunits by immunoblotting. PI31 knockdown reduced levels of immunoproteasome-specific subunits, such as PSMB8 (β-5i) and PA28a compared with control cells. Of note, PI31 knockdown did not alter the expression of constitutive proteasome subunits, such as PSMD2, PSMA4 (α4) and PMSA2 (α2) ( fig. 3I ). Together these results show a previously unidentified cell intrinsic role for PI31 in immune cells to modulate the generation of HLA class I-associated peptides, partially through stabilising immunoproteasome subunit composition.
SEC16A forms a complex with PI31 and TBK1
To identify interaction partners of PI31, we immunoprecipitated PI31 from NOD2 and TLR2 stimulated DCs, followed by performing tryptic digestion and mass spectrometry analysis ( fig.   4A ). After NOD2 and TLR2 stimulation, we detected SEC16A as the protein with the highest confidence score and number of unique peptides ( fig. 4B, C) . SEC16A is an endoplasmic reticulum (ER) protein that marks ER exit sites (ERES) in mammalian cells and is implicated in ER to Golgi vesicular trafficking (42), so we sought to confirm an interaction between PI31 and SEC16A. We immunoprecipitated PI31 in both primary DCs and THP1 cells following NOD2 activation and examined SEC16A levels by western blot. This result confirmed the presence of PI31 and SEC16A in the same protein complex in both non-stimulated and stimulated samples, though increased SEC16A levels occurred in samples stimulated with MDP and PAM 3 CSK 4 ( fig.   4D , E). We then overexpressed GFP-tagged PI31 in THP1 cells and assessed co-localization with SEC16A by confocal microscopy. We observed a significantly enriched co-localization of PI31 and SEC16A, which was dependent on NOD2 and TLR2 signals in DCs ( fig. 4F, G) . Given the direct association of PI31 with TBK1, we tested whether SEC16A and TBK1 are present in the same protein complex. So, we immunoprecipitated endogenous TBK1 in THP1 cells and examined levels of SEC16A by western blot. Co-immunoprecipitation confirmed the association of TBK1 and SEC16A in the same protein complex ( fig. 4H ).
As SEC16A is a protein implicated in vesicular trafficking from the ER, we next examined whether NOD2 and TLR2 stimulation could control SEC16A recruitment to phagosomes carrying components of PGN. We treated BMDCs from WT mice with streptavidin beads conjugated to biotinylated MDP and PAM 3 CSK 4 and examined cellular localization of SEC16A by confocal microscopy. Phagosomes bearing beads with or without MDP and PAM 3 CSK 4 failed to acquire SEC16A ( fig. S4A ). We confirmed these findings by examining LAMP1 levels by immunoblot following stimulation of BMDCs with streptavidin beads conjugated to biotinylated MDP, PAM 3 CSK 4 and LPS. While SEC16A, TBK1 and PI31 were not enriched in phagosomes carrying beads, they were enriched only in whole cell extracts (WCE) when the ER resident ERp72 was detected. Phagosomal lysates showed enriched LAMP-1 with significantly increased levels on phagosome carrying beads conjugated to MDP/PAM 3 CSK 4 and LPS ( fig. S4B) .
These results indicate a novel association between PI31 and SEC16A, a component of endoplasmic reticulum exit sites (ERES), required for secretory cargo traffic from the ER to the Golgi apparatus. We demonstrated that the levels of PI31 and SEC16A in this complex are increased on NOD2 and TLR2 sensing. We further demonstrated the association of TBK1 in the same protein complex.
PI31 modulate NOD2/TLR2-dependent cross-presentation and CD8 + T cell activation
Studies demonstrated that PRR signaling, including NOD2, increases CD8 + T cell activation by enhancing cross-presentation (43, 27, 44) . However, the mechanisms underlying the effects of PRR engagement on antigen presentation are incompletely understood. We determined the impact of NOD2 and TLR2 dependent phosphorylation of PI31 on cross-presentation by downregulating PI31 expression by siRNA knockdown in DCs derived from the bone marrow (BMDC) from wild-type (WT) mice stimulated with MDP and PAM 3 CSK 4 and pulsed with full length ovalbumin (OVA) ( fig. 5A ) and quantified CD8 + T cell activation through increased CD69 expression. We found significantly reduced cross-presentation of OVA to OT-I T cells in BMDCs expressing low levels of PI31 compared to cells expressing PI31 ( fig. 5B ). In contrast, we found the octapeptide SIINFEKL (OVA amino acids 257-264), which is directly recognized by OT-I T cells and does not require proteasomal degradation, was presented with equal efficiency by BMDCs expressing normal or reduced levels of PI31 ( fig. 5C ). These data indicate that cross-presentation requires PI31 in DCs stimulated with NOD2 and TLR2 ligands.
Then, we investigated whether the PI31 binding partner, SEC16A, also increased crosspresentation during stimulation with NOD2 and TLR2. We knocked down SEC16A expression in BMDCs ( fig. 5D ), followed by stimulation with MDP and PAM 3 CSK 4 plus ovalbumin (OVA).
We assessed cross-presentation to CD8 + TCR transgenic OT-I T cells as previously described.
We found no change in cross-presentation of OVA to OT-I T cells in BMDCs expressing low levels of SEC16A compared to cells expressing SEC16A ( fig. 5E ). We found an equal efficiency in presentation of SIIFENKL by BMDCs expressing normal or reduced PI31 levels ( fig. 5F ).
Although SEC16A forms a complex with PI31 on NOD2 triggering, these results suggest that it is not required to modulate cross-presentation. Thus, NOD2/TLR2 mediated MHC class I antigen presentation requires PI31, but not SEC16A, in vitro.
TBK1 inhibition prevents cross-presentation
To investigate whether the involvement of NOD2/TLR2-dependent cross-presentation requires TBK1 activity, we pretreated BMDCs from WT mice with the TBK1 specific inhibitor, BX795, followed by stimulation with MDP and PAM 3 CSK 4 and OVA. Treatment with BX795 significantly reduced cross-presentation of OVA to OT-I T cells in BMDCs compared to control cells ( fig. 6A ), while the octapeptide SIINFEKL was presented with equal efficiency by MDP and PAM 3 CSK 4 stimulated BMDCs with or without BX795 ( fig. 6B ). Then, we investigated whether NOD2/TLR2-dependent TBK1 activity also promoted cross-presentation in DCs in vivo.
We treated WT mice with Amlexanox, which blocks TBK1 activity in vivo without affecting the activity of IKK-α or IKK-β or any other known kinases (45, 46) . We administered Amlexanox intraperitoneally (i.p.) and administered a second injection of the inhibitor after 24 hrs accompanied by i.p. injection of MDP and PAM 3 CSK 4 . After 12 hrs, we injected mice with OVA, isolated total splenic CD11c + cells and co-cultured them with OT-I CD8 + T cells to measure antigen-specific T cell activation ( fig. 6C ).
First, we tested whether stimulation with MDP and PAM 3 CSK 4 enhanced activation of DCs by assessing expression of DC activation markers. NOD2 and TLR2 stimulation significantly increased expression of MHC-II, CD86, CD40, but not MHC-I, compared to control mice.
Treatment with Amlexanox did not change the expression of MHC-II, CD40 and MHC-I ( fig.   6D , E). We assessed OT-I CD8 + T cell specific activation by examining the percentage of proliferation measured by CFSE dye dilution. Of note, DCs from mice pre-treated with Amlexanox cross-presented OVA significantly less than untreated mice ( fig. 6F, G) . We conclude that enhanced MHC class I cross presentation mediated by DCs activated in vivo with MDP and PAM 3 CSK 4 requires TBK1 activity.
DCs expressing NOD2 variants from Crohn's disease show defective cross-presentation
Polymorphisms in NOD2 represent the strongest known genetic risk factors associated with the development of Crohn's disease (47). So, we investigated whether Crohn's patients DCs expressing variants of NOD2 exhibited defects in cross-presentation after NOD2 stimulation.
We used HLA-A2 DCs from healthy individuals expressing wild type (WT) NOD2 or HLA-A2
Crohn's patients DCs expressing Crohn's associated NOD2 polymorphisms. We assessed the cross-presentation ability of DCs using the NY-ESO-1 specific CD8 + CTL clones generated by directly sorting HLA-A2 NY-ESO-1 157-165 tetramers from a melanoma patient (48, 28 The interplay between NOD2 and TLR2 has been well characterized and it is not surprising given that both receptors respond to adjacent components of PGN expressed on bacterial cell walls, MDP and PAM 3 CSK 4 respectively (10, 6, 7, 11, 54, 9) . Upon MDP recognition, NOD2 recruits RIPK2, which induces activation of the IKK complex. IKK phosphorylates IκBα, targeting it for Lys48-linked polyubiquitination and proteasome-dependent degradation facilitating NF-κB translocation into the nucleus (55, 31) . This signaling pathway, in physiological conditions, amplifies TLR2 signals and both synergize in the induction of NF-κB, which play a central role in cytokine production (56, 7, 57, 58 the cross-presentation pathway drives CD8 + T cell activation and in the presence of Crohn's associated NOD2 polymorphisms impairs these responses. As a result of impaired T cell mediated clearance of commensal microbes, we expect loss of function NOD2 mutations to impair antigen presentation leading to non-specific intestinal inflammation. The adjuvant activity of MDP and TLR ligands is well known to enhance vaccine responses (69). Here, we define the molecular basis for this adjuvancy. We speculate that biochemically disparate forms of PGN derived from different bacterial species may affect immunoproteasome stability and antigen presentation to different degrees. 
Figure legends
